RxDoctor Payments Data

Luke Basdeo, MD

Nephrology · Port Orange, FLNPI 1427491729

Payments from drug & device makers

$56,377in general payments, 2019–2025

Across 133 payments — averaging $423.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Outset Medical Inc$54K
  • Mallinckrodt Hospital Products Inc.$442
  • Amgen$387
  • Vifor Pharma, Inc.$136
  • Renalytix AI, Inc.$134
  • Otsuka America Pharmaceutical, Inc.$129
  • plus $709 from 12 others

What the payments were for

  • Consulting fees$14,12325%
  • Speaking & faculty fees$28,00050%
  • Travel & lodging$10,58219%
  • Food & beverage$3,5446%
  • Education$1280%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$56,377 in reported general payments places this provider in the 85th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$349,159
Medicare patients
462
Services billed
2,268

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide22$82,494
FarxigaDapagliflozin Propanediol30$41,337
LokelmaSodium Zirconium Cyclosilicate13$9,079
Sevelamer Carbonate18$2,416
Nifedipine ErNifedipine66$1,995
Calcium Acetate16$1,971
Valsartan42$1,730
Bumetanide34$1,630
Midodrine Hcl16$1,244
Furosemide115$769
Tamsulosin Hcl42$702
Potassium Chloride40$620
Hydralazine Hcl28$463
Torsemide17$417
Mirtazapine13$415

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$115$82,49422 claims
AstraZenecaFarxiga, Lokelma$110$50,41543 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 756 nephrology providers in Florida.

Other nephrology in Port Orange

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →